Genscript Biotech Corporation (G51) - Total Liabilities

Latest as of December 2025: €888.59 Million EUR ≈ $1.04 Billion USD

Based on the latest financial reports, Genscript Biotech Corporation (G51) has total liabilities worth €888.59 Million EUR (≈ $1.04 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check G51 financial resilience to evaluate the company's liquid asset resilience ratio.

Genscript Biotech Corporation - Total Liabilities Trend (2016–2025)

This chart illustrates how Genscript Biotech Corporation's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see G51 total asset value.

Genscript Biotech Corporation Competitors by Total Liabilities

The table below lists competitors of Genscript Biotech Corporation ranked by their total liabilities.

Company	Country	Total Liabilities
Addsino Co Ltd SHE:000547	China	CN¥4.14 Billion
National Storage Affiliates Trust NYSE:NSA	USA	$3.56 Billion
Ninestar Corp SHE:002180	China	CN¥7.51 Billion
Impinj Inc NASDAQ:PI	USA	$335.95 Million
Curbline Properties Corp. NYSE:CURB	USA	$748.85 Million
Alliance Resource Partners LP NASDAQ:ARLP	USA	$1.16 Billion
Chunghwa Precision Test Tech Co Ltd TWO:6510	Taiwan	NT$1.17 Billion
Zhuzhou Hongda Electronics Corp Ltd Class A SHE:300726	China	CN¥528.27 Million

Liability Composition Analysis (2016–2025)

This chart breaks down Genscript Biotech Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See G51 equity financing ratio to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.50	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.22	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.18	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Genscript Biotech Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Genscript Biotech Corporation (2016–2025)

The table below shows the annual total liabilities of Genscript Biotech Corporation from 2016 to 2025.

Year	Total Liabilities	Change
2025-12-31	€888.59 Million ≈ $1.04 Billion	-6.95%
2024-12-31	€954.91 Million ≈ $1.12 Billion	-28.89%
2023-12-31	€1.34 Billion ≈ $1.57 Billion	+13.45%
2022-12-31	€1.18 Billion ≈ $1.38 Billion	+3.85%
2021-12-31	€1.14 Billion ≈ $1.33 Billion	+80.40%
2020-12-31	€631.82 Million ≈ $738.66 Million	+22.18%
2019-12-31	€517.11 Million ≈ $604.56 Million	+22.05%
2018-12-31	€423.68 Million ≈ $495.32 Million	+53.54%
2017-12-31	€275.94 Million ≈ $322.61 Million	+556.84%
2016-12-31	€42.01 Million ≈ $49.12 Million	--

About Genscript Biotech Corporation

F:G51 Germany Biotechnology

Market Cap

$8.94 Billion

€7.65 Billion EUR

Market Cap Rank

#4583 Global

#783 in Germany

Share Price

€3.50

Change (1 day)

-5.41%

52-Week Range

€1.14 - €3.94

All Time High

€4.62